每经记者|金喆 每经编辑|张海妮5月30日,美国生物技术公司Summit Therapeutics(SMMT.US)宣布了依沃西单抗全球Ⅲ期临床试验HARMONi研究的顶线结果。依沃西单抗是一款PD-1/VEGF双抗,由国内创新药公司康方生物(09926.HK,股价83.800港元,市值752.18亿港元)研发。2022年12月,康方生物将该药海外权益授予Summit。去年5月,康方生物首先...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.